Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Corgenix Announces Initial Phase Completion of Clinical Trial of Rapid Test for Lassa Fever

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
First-to-market, point-of-care rapid diagnostic test based on recombinant antigen technology for the detection of Lassa viral hemorrhagic fever filed for CE Marking.

Corgenix Medical Corporation announced completion of a major phase of the collaborative effort to combat important viral diseases.

The multi-year study, conducted primarily at the Kenema Government Hospital in Kenema, Sierra Leone, is investigating the clinical utility of several diagnostic products developed by Corgenix and other members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University. In this major study, scientists are using Consortium-developed recombinant antigen-based tests to evaluate patients presenting with clinical symptoms of Lassa hemorrhagic fever. Lassa fever is a dangerous, often fatal disease common to much of West Africa and is considered to be a bioterror threat throughout the world.

“We are very pleased to successfully complete the initial clinical testing phase of our Lassa product development program,” said Douglass Simpson, Corgenix President and CEO. “The first product, a rapid 15-minute test that detects Lassa virus antigen in blood, demonstrated outstanding clinical performance in our studies. It showed its potential to dramatically change the way this disease is detected and treated, with healthcare workers now able to diagnose Lassa infections in the early acute stage, leading to earlier treatment and potentially saving many lives.”

Corgenix said that the first of the products used in the studies, the ReLASVTM Antigen Rapid Test, will be advanced into full commercialization this year. Corgenix has submitted the study results to secure CE Marking, a regulatory requirement in Europe and many other countries.

Lassa virus is a category-A select agent, requiring biosafety level 4 (BSL-4) laboratories. It poses a high individual risk of aerosol-transmitted laboratory infections that cause severe to fatal disease in humans for which vaccines or other treatments are not available. Lassa virus causes Lassa hemorrhagic fever characterized by bleeding and coagulation abnormalities, with mortality rates reported exceeding 25 percent, with children and pregnant women being the highest risk groups. This new rapid test serves the urgent need for screening of suspected Lassa fever cases in the early stages of infection when patients exhibit milder symptoms that can lead to misdiagnosis.

Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine and Principal Investigator of the Consortium, added, “We have been very pleased with the results of our collaborative effort over the past years. The diagnostic products for Lassa have shown to be remarkably effective in clinical settings in Africa and will have a meaningful impact on the health care in that part of the world, and will also fill a critical gap in bioterrorism defense.”

The Consortium will continue its research activities in Sierra Leone, Nigeria and other West African countries, advancing other laboratory tests for Lassa and other tropical viral diseases. The research will also assess the potential impact these new generation diagnostic products have on significantly reducing mortality rates through earlier treatment.

The Consortium Lassa products have not yet been cleared for use in the United States by the U.S. Food and Drug Administration (FDA).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Corgenix Announces Partnership with Health Diagnostic Laboratory
Corgenix Medical Corporation has announced a strategic partnership with Health Diagnostic Laboratory, Inc. for the development of a clinical Laboratory Developed Test.
Thursday, October 31, 2013
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!